Amneal Pharmaceuticals Inc (AMRX)
6.815
+0.06
(+0.96%)
USD |
NASDAQ |
May 17, 16:00
6.815
0.00 (0.00%)
After-Hours: 20:00
Amneal Pharmaceuticals Revenue (Quarterly): 659.19M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 659.19M |
| December 31, 2023 | 616.98M |
| September 30, 2023 | 620.04M |
| June 30, 2023 | 599.05M |
| March 31, 2023 | 557.54M |
| December 31, 2022 | 609.76M |
| September 30, 2022 | 545.56M |
| June 30, 2022 | 559.36M |
| March 31, 2022 | 497.63M |
| December 31, 2021 | 536.90M |
| September 30, 2021 | 528.59M |
| June 30, 2021 | 535.08M |
| March 31, 2021 | 493.10M |
| December 31, 2020 | 510.03M |
| Date | Value |
|---|---|
| September 30, 2020 | 519.29M |
| June 30, 2020 | 464.66M |
| March 31, 2020 | 498.53M |
| December 31, 2019 | 397.33M |
| September 30, 2019 | 378.28M |
| June 30, 2019 | 404.64M |
| March 31, 2019 | 446.12M |
| December 31, 2018 | 497.53M |
| September 30, 2018 | 476.49M |
| June 30, 2018 | 413.79M |
| March 31, 2018 | 275.19M |
| December 31, 2017 | 293.37M |
| September 30, 2017 | 254.73M |
| June 30, 2017 | 259.87M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
378.28M
Minimum
Sep 2019
659.19M
Maximum
Mar 2024
526.58M
Average
531.83M
Median
Revenue (Quarterly) Benchmarks
| Fate Therapeutics Inc | 1.925M |
| Ocular Therapeutix Inc | 14.77M |
| Editas Medicine Inc | 1.135M |
| AnaptysBio Inc | 7.179M |
| AEON Biopharma Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -91.64M |
| Total Expenses (Quarterly) | 575.96M |
| EPS Diluted (Quarterly) | -0.30 |
| Enterprise Value | 4.738B |
| Gross Profit Margin (Quarterly) | 36.11% |
| Profit Margin (Quarterly) | -13.90% |
| Earnings Yield | -10.85% |
| Operating Earnings Yield | 18.31% |
| Normalized Earnings Yield | -7.252 |